1e
19
1
49
2
2
18
1b
1d
18
37
42
1d
2 29
1d
25
Matthew J. Dougherty, M.D
78
42
Professor of Clinical Surgery
28
81
3
5e
Assistant Surgeon to the Hospital, Pennsylvania Hospital, Philadelphia, PA
76
Chief, Endovascular Surgery, Pennsylvania Hospital, Philadelphia, PA
7
11
Department: Surgery
4
1
b
1d
46
Contact information
4a
4
3
3
3
2
4
b
1f
4a
Division of Vascular Surgery
1d Pennsylvania Hospital
3f Suite 101, 700 Spruce Street
Philadelphia, PA 19104
26
1d Pennsylvania Hospital
3f Suite 101, 700 Spruce Street
Philadelphia, PA 19104
2e
Office: 215-829-5000
30
b3
12
30
13
Education:
21 8 B.A c
44 University of Virginia, Charlottesville, VA, 1980.
21 9 M.D. c
3b Harvard Medical School, Boston, MA, 1984.
c
3
3
3
3
8a
Permanent link21 8 B.A c
44 University of Virginia, Charlottesville, VA, 1980.
21 9 M.D. c
3b Harvard Medical School, Boston, MA, 1984.
c
2 29
21
1e
1d
24
5e
60 EUCLID is a randomized, double-blind, parallel group, multi-center study evaluating the
5f efficacy of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) in reducing
61 the primary endpoint - a composite of CV death, MI or ischemic stroke - in patients with
d PAD.
8
10 2012-2015
26 7 1d 1f
27
Description of Research Expertise
60 Principal Site Investigator EUCLID Study (Examining Use of tiCagreLor In paD).60 EUCLID is a randomized, double-blind, parallel group, multi-center study evaluating the
5f efficacy of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) in reducing
61 the primary endpoint - a composite of CV death, MI or ischemic stroke - in patients with
d PAD.
8
10 2012-2015
26 7 1d 1f